Biotechnology startup Nuvig Therapeutics is the latest emerging immune drug developer to attract investors’ attention, announcing Thursday a $161 million Series B round to bring its lead candidate into mid-stage testing.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,